EXPD
45
8
MAS
56
5
STI
31
-16
PWR
72
2
THC
55
-4
SLG
66
2
HD
55
8
ALL
51
8
PNR
69
4
GILD
49
2
MRO
40
-15
GM
68
3
PRU
62
5
VNO
50
-9
APA
24
3
EXC
56
2
PDCO
38
3
DGX
50
2
BF.B
31
3
NKE
30
2
EXPD
45
8
MAS
56
5
STI
31
-16
PWR
72
2
THC
55
-4
SLG
66
2
HD
55
8
ALL
51
8
PNR
69
4
GILD
49
2
MRO
40
-15
GM
68
3
PRU
62
5
VNO
50
-9
APA
24
3
EXC
56
2
PDCO
38
3
DGX
50
2
BF.B
31
3
NKE
30
2
Financhill
Back

Zevra Therapeutics Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.25/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
67

ZVRA
Zevra Therapeutics

Last Price:
9.15
Seasonality Move:
6.65%

7 Day Trial

ALL ACCESS PASS

$ 7

Start Investing Smarter Unlock Louis Navellier's Stock Grader for free

Louis' clients have paid up to $30,000 for these insights - now you can try it at no cost.

Zevra Therapeutics Price Quote

$9.15
+0.02 (+2.01%)
(Updated: November 22, 2024 at 5:52 AM ET)

Zevra Therapeutics Key Stats

Buy
67
Zevra Therapeutics (ZVRA) is a Buy
Day range:
$8.90 - $9.30
52-week range:
$4.20 - $9.30
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
15.86
P/B ratio:
6.98%
Volume:
458.2K
Avg. volume:
626.7K
1-year change:
102.44%
Market cap:
$487.3M
Revenue:
$27.5M
EPS:
$-2.11

How Much Does Zevra Therapeutics Make?

Is Zevra Therapeutics Growing As A Company?

  • What Is Zevra Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.28%
  • What Is Zevra Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Zevra Therapeutics Stock Price Performance

What Is Zevra Therapeutics 52-Week High & Low?

Zevra Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Zevra Therapeutics?

  • How Much Debt Does Zevra Therapeutics Have?
    Total long term debt quarterly is $58.9M
  • How Much Cash Does Zevra Therapeutics Have?
    Cash and short term investments quarterly total is $89.4M
  • What Is Zevra Therapeutics’s Book Value Per Share?
    Book value per share is 1.31

Is Zevra Therapeutics Cash Flow Positive?

  • What Is ZVRA Cash Flow From Operations?
    Cash flow from operations (TTM) is -$69.6M
  • What Is Zevra Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $86.3M
  • What Is Zevra Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$6.1M

Zevra Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    ZVRA return on invested capital is -85.03%
  • What Is Zevra Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -56.14%
  • What Is ZVRA Return On Equity?
    ROE is a measure of profitability and is -159.89%

Zevra Therapeutics Earnings Date & Stock Price

Zevra Therapeutics Competitors

  • Who Are Zevra Therapeutics's Competitors?
    Below is a list of companies who compete with Zevra Therapeutics or are related in some way:
    • BioCardia Inc (BCDA)
    • Ionis Pharmaceuticals Inc (IONS)
    • Instil Bio Inc (TIL)
    • Vanda Pharmaceuticals Inc (VNDA)
    • Xeris Biopharma Holdings Inc (XERS)

Zevra Therapeutics Dividend Yield

Zevra Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -68.29%
Revenue: 27.63% -24.01%

Analyst Recommendations

Buy Recommendations: 4
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 20.14
Upside from Last Price: 120.62%

Major Shareholders

  • How many ZVRA shares are owned by institutional investors?
    35.4M ZVRA shares are owned by institutional investors
  • How many ZVRA shares are owned by insiders?
    286.6K ZVRA shares are owned by insiders